Broad Health Condition Anaesthesiology
Neurological
Mental Health
Neurological
Neurological
Neurological
Neurological
Oral and Gastrointestinal

Specific Health ConditionPain management
Epilepsy
Other mental health disorders
Other neurological disorders
Parkinson's disease
Dementias
Multiple sclerosis
Inflammatory bowel disease

Trial Focus

Recruitment statusRecruiting

Recruitment Details
Recruitment State
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Anticipated date of first participant enrolment20/07/2020

Anticipated date of last participant enrolment20/07/2020

Phase of TrialNot Applicable

Has the study received ethics approval?Approved

Trial summary

This study is a multicenter, open label, longitudinal observational study aiming to assess the safety, tolerability and efficacy of MediCabilis™ when used at the prescribed dose by physicians for different indications using data reported by patients during treatment. 

Key inclusion criteria

Participants will be any patient who has been prescribed MediCabilis through the Special Access Scheme B or by an authorised prescriber. 
Participants may be taking MediCabilis in any dose, form, duration and free
quency, and for any condition. 
Patients of any gender who is equal or greater than 18 years may participate.
Prospective patients that understand the informed consent process and to give informed consent to participate in the study. 
Diagnosis of their condition/disease confirmed by patient’s GP or specialist.

Prospective participants agree to abstain from using illicit cannabis products for the duration of their participation in the study.

Minimum age18 Years

GenderBoth males and females

Can Healthy volunteers participate?No

Key exclusion criteria

Any severe cognitive, intellectual disability, medical or psychiatric condition that impairs the participant’s ability to provide informed consent.
Patients who are using illicit forms of cannabis.